Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson's disease
- Details
- Category: Bayer
Bayer AG announced today that BlueRock Therapeutics (BlueRock), a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, successfully administered the first dose of its pluripotent stem cell-derived dopaminergic neurons, named DA01, to a Parkinson's disease patient in their open-label Phase 1 clinical study.
Pfizer and BioNTech receive first authorization in European Union for COVID-19 vaccine in adolescents
- Details
- Category: Business
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the Conditional Marketing Authorization (CMA) for COMIRNATY® in the European Union (EU) has been expanded to include individuals 12 to 15 years of age. This follows the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine in this age group.
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
- Details
- Category: Novartis
Novartis and Molecular Partners announced the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin® therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis will conduct the clinical trial program for ensovibep, with Molecular Partners as sponsor of the studies.
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
- Details
- Category: GlaxoSmithKline
Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate. The global randomized, double-blind, placebo-controlled Phase 3 study will include more than 35,000 volunteers aged 18 and older from several countries, including sites in the US, Asia, Africa and Latin America.
Pfizer and BioNTech to supply the European Union with up to 1.8 billion additional doses of COMIRNATY®
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses.
European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan
- Details
- Category: AstraZeneca
AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2.
More Pharma News ...
- Takeda announces approval of Moderna's COVID-19 vaccine in Japan
- Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
- Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
- Lilly and MiNA Therapeutics announce saRNA research collaboration
- Vaccination with Sputnik V launched in India
- Second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates high immunogenicity against virus variants in preclinical study
- Novavax Announces positive preclinical data for combination influenza and COVID-19 vaccine candidate